Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Somapacitan once weekly vs daily Norditropin in short-stature children (SGA, Turner, Noonan, ISS)
2023-506927-27-00Phase 3Authorised
- Sponsor
- Novo Nordisk
- Start
- Aug 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 32
01
Overview
Phase 3, randomised trial of somapacitan in growth disorder, Turner syndrome (TS), Noonan syndrome and 1 more (2 arms), sponsored by Novo Nordisk. Primary endpoint: Height velocity. Planned start Aug 2022; status: authorised.
02
Drugs
somapacitan
03
Conditions
growth disorderTurner syndrome (TS)Noonan syndromeIdiopathic Short Stature (ISS)
Beyond the preview
Go deeper on 2023-506927-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506927-27-00.